RE: Rns & no prices to buy @ 24p8 Apr 2025 11:12
Commercial agreement
SkinBioTherapeutics finalised commercial terms with Croda following successful additional studies of its skin lysate. The terms include tiered royalties based on global sales revenues on any licensed products derived from the partnership.
Under the terms of the agreement, all details about formulation, functionality and Croda's financial expectations remain confidential due to the competitiveness of the cosmetics market. Any royalty revenues arising from future sales will be reported to the market at the appropriate time.
Stuart Ashman, CEO of SkinBioTherapeutics, said:
"The international launch of Zenakine™ by Croda has been a long anticipated event for the SkinBioTherapeutics team and our investors. We could not be more delighted with the initial launch impact and the excitement of the Croda team to be able to talk about Zenakine™ to the global industry at long last.
"Croda is reporting that this is the first scientifically proven active ingredient for anti-ageing application, and together with the formulation options in their marketing literature, tells a compelling story to the cosmetics industry. We will be monitoring initial industry interest on the ground for this first range of applications."
Does that mean revenue already received can be reported or is that another badly worded RNS?